BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 25152312)

  • 1. Molecular genetic biomarkers in myeloid malignancies.
    Matynia AP; Szankasi P; Shen W; Kelley TW
    Arch Pathol Lab Med; 2015 May; 139(5):594-601. PubMed ID: 25152312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms.
    Patel U; Luthra R; Medeiros LJ; Patel KP
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S62-S74. PubMed ID: 28760304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
    Kohlmann A; Bacher U; Schnittger S; Haferlach T
    Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies.
    McDevitt MA
    Semin Oncol; 2012 Feb; 39(1):109-22. PubMed ID: 22289497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Tremblay D; Sokol K; Bhalla S; Rampal R; Mascarenhas JO
    Oncology (Williston Park); 2018 Apr; 32(4):e38-e44. PubMed ID: 29684235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications.
    Malcovati L; Ambaglio I; Elena C
    Curr Opin Oncol; 2015 Nov; 27(6):551-9. PubMed ID: 26352542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular findings in myeloid neoplasms.
    Tran TB; Siddon AJ
    Int J Lab Hematol; 2023 Aug; 45(4):442-448. PubMed ID: 37345257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.
    Zhang L; Padron E; Lancet J
    Leuk Res; 2015 Jan; 39(1):6-17. PubMed ID: 25465125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants Associated with Myelodysplastic Syndrome in Myeloid Malignancies.
    Jiang L; Pallavajjala A; Huang J; Haley L; Morsberger L; Stinnett V; Hardy M; Park R; Ament C; Finch A; Shane A; Parish R; Nozari A; Long P; Adams E; Smith K; Parimi V; Dougaparsad S; Long L; Gocke CD; Zou YS
    J Mol Diagn; 2021 Apr; 23(4):467-483. PubMed ID: 33577993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.
    Hughes CFM; Gallipoli P; Agarwal R
    Pathology; 2021 Apr; 53(3):328-338. PubMed ID: 33676768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary.
    Király AP; Kállay K; Gángó A; Kellner Á; Egyed M; Szőke A; Kiss R; Vályi-Nagy I; Csomor J; Matolcsy A; Bödör C
    Pathol Oncol Res; 2018 Jan; 24(1):83-88. PubMed ID: 28357685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.
    Bacher U; Shumilov E; Flach J; Porret N; Joncourt R; Wiedemann G; Fiedler M; Novak U; Amstutz U; Pabst T
    Blood Cancer J; 2018 Nov; 8(11):113. PubMed ID: 30420667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay.
    Ferrone CK; Wong H; Semenuk L; Werunga B; Snetsinger B; Zhang X; Zhang G; Lui J; Richard-Carpentier G; Crocker S; Good D; Hay AE; Quest G; Carson N; Feilotter HE; Rauh MJ
    J Mol Diagn; 2021 Oct; 23(10):1292-1305. PubMed ID: 34365012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biology and clinical impact of genetic lesions in myeloid malignancies.
    Lindsley RC; Ebert BL
    Blood; 2013 Nov; 122(23):3741-8. PubMed ID: 23954890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
    Forghieri F; Paolini A; Morselli M; Bigliardi S; Bonacorsi G; Leonardi G; Coluccio V; Maccaferri M; Fantuzzi V; Faglioni L; Colaci E; Soci F; Nasillo V; Messerotti A; Arletti L; Pioli V; Zucchini P; Quadrelli C; Corradini G; Giacobbi F; Vallerini D; Riva G; Barozzi P; Lagreca I; Marasca R; Narni F; Mecucci C; Ottaviani E; Martinelli G; Falini B; Luppi M; Potenza L
    Leuk Lymphoma; 2015; 56(11):3222-6. PubMed ID: 25813079
    [No Abstract]   [Full Text] [Related]  

  • 16. Genetic basis of myelodysplastic syndromes.
    Ogawa S
    Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(3):107-121. PubMed ID: 32161209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies.
    Wang X; Muramatsu H; Okuno Y; Sakaguchi H; Yoshida K; Kawashima N; Xu Y; Shiraishi Y; Chiba K; Tanaka H; Saito S; Nakazawa Y; Masunari T; Hirose T; Elmahdi S; Narita A; Doisaki S; Ismael O; Makishima H; Hama A; Miyano S; Takahashi Y; Ogawa S; Kojima S
    Haematologica; 2015 Oct; 100(10):e398-401. PubMed ID: 26022708
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetics of myeloid malignancies: pathogenetic and clinical implications.
    Fröhling S; Scholl C; Gilliland DG; Levine RL
    J Clin Oncol; 2005 Sep; 23(26):6285-95. PubMed ID: 16155011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia.
    Higgins A; Shah MV
    Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32640569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms.
    Kanagal-Shamanna R; Hodge JC; Tucker T; Shetty S; Yenamandra A; Dixon-McIver A; Bryke C; Huxley E; Lennon PA; Raca G; Xu X; Jeffries S; Quintero-Rivera F; Greipp PT; Slovak ML; Iqbal MA; Fang M
    Cancer Genet; 2018 Dec; 228-229():197-217. PubMed ID: 30377088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.